Patient Access to Affordable Medicines: How a Renegotiated NAFTA Could Keep Drug Prices High

Wednesday September 12, 2018

Friday, September 14, 2018
Noon–1:00 p.m.

1310 Longworth House Office Building
Committee on House Administration Hearing Room

On August 31, President Trump notified Congress of his intent to sign a trade agreement with Mexico. This agreement could have a significant impact on the United States’ economy, including prescription drug pricing and the emerging biosimilars market.

Please join the Association for Accessible Medicines (AAM) for a briefing to discuss the proposed NAFTA agreement, its impact on rising prescription drug prices and recommendations for a stronger agreement.

Panelists include:

Jeff Francer (Moderator)
Senior Vice President and General Counsel, Association for Accessible Medicines

Marcie McClintic Coates
Head of Global Policy, Mylan

David Mitchell 
President and Founder, Patients for Affordable Drugs

Leigh Purvis
Director, Health Services Research, AARP

This briefing has been designed to comply with House and Senate ethics rules. Lunch will be provided.

To RSVP, contact Lindsey Novak

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.


Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:



October 21–23, 2024 | Rockville, MD

GRx+Biosims™ 2024 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Access the most recent information straight from experts at the Food and Drug Administration, grasp the latest policies shaping the industry, and acquire valuable insights to propel your professional development.